Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference

Research output: Contribution to journalArticle

Abstract

T-cell-depleted hematopoietic stem cell (HSC) transplantation from an HLA-haploidentical relative (Haplo HSCT) may represent a suitable and effective transplant option, as it is capable of rescuing not only adult patients with high-risk acute myeloid leukemias (AML) but also children with relapsed acute lymphoblastic leukemia (ALL), as shown by the two representative cases presented in this study. In Haplo HSCT, the anti-leukemia effect is mediated by "alloreactive" (i.e. KIR/HLA-mismatched) NK cells originated from donor HSCs. The availability of suitable KIR-specific monoclonal antibodies allows the prompt identification of alloreactive NK cell subsets as well as their quantification. This is important for selection of the most suitable donor and evaluation of the generation and persistence of these alloreactive NK cells after transplantation. In view of the favorable clinical outcome of children with chemo-resistant ALL, Haplo HSCT from an NK-alloreactive relative could become a first option in these high-risk leukemia patients.

Original languageEnglish
Pages (from-to)171-178
Number of pages8
JournalClinical Immunology
Volume133
Issue number2
DOIs
Publication statusPublished - Nov 2009

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Killer Ig-like receptors
  • Leukemia
  • NK cells

ASJC Scopus subject areas

  • Immunology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Haploidentical hemopoietic stem cell transplantation for the treatment of high-risk leukemias: How NK cells make the difference'. Together they form a unique fingerprint.

  • Cite this